View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 24, 2021updated 11 Jul 2022 9:51am

Tiziana and FHI Clinical work on Phase II intranasal Covid-19 drug trial

The trial will monitor the attenuation of pulmonary pathology in 80 participants enrolled at up to seven study sites in Brazil. 

Tiziana Life Sciences has entered an agreement with FHI Clinical to carry out a Phase II proof-of-concept clinical trial of intranasal Foralumab in severe Covid-19 patients hospitalised with pulmonary inflammation in Brazil.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Foralumab is a fully human anti-CD3 monoclonal antibody. The nasal and oral doses of the drug showed an ability to stimulate Tregs in animal studies and could be used as immunotherapy for autoimmune as well as inflammatory diseases.

Tiziana announced plans to commence the Phase II trial of Foralumab in Brazil in March this year.

The randomised, placebo-controlled, double-blind trial will assess the safety, tolerability and efficacy of intranasal doses of Foralumab in subjects with severe Covid-19.

It will evaluate pulmonary pathology attenuation in 80 subjects enrolled at up to seven study centres in Brazil.

The participants will be given 100µg Foralumab intranasally using a metered-dose nasal atomisation device or placebo.

The effect of the antibody on symptoms resolution will also be analysed using chest computerised tomography, inflammatory biomarkers, T-cell subpopulations, safety and mucosal inflammatory response after 14 days of treatment.

FHI Clinical, an FHI 360 subsidiary, will leverage its past outbreak experience to support the trial.

Tiziana Life Sciences chief medical officer Dr Neil Graham said: “After a successful proof-of-mechanism trial in mild to moderate Covid-19 outpatients with intranasal Foralumab earlier this year, the next step is to test it in more severe hospitalised patients with pulmonary inflammation.”

Separately, Mercaptor Discoveries has decided to progress its antiepileptic drug candidate (AED), MD-004, into the clinic for treating brain inflammation observed in long COVID patients.

The efficacy and safety profiles of MD-004 are favourable to advance the drug as an AED, which can potentially stop a seizure before it begins. The drug showed reproducible pharmacokinetic, pharmacodynamic, efficacy and safety data in several preclinical studies.

MD-004 is set to enter the clinic next year, Mercaptor noted.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology